Stoke Therapeutics (NASDAQ:STOK) Reaches New 52-Week High - Time to Buy?

Key Points

• Stoke Therapeutics shares reached a new 52-week high of $21.87, with analysts maintaining a generally positive outlook, as two analysts rated it a Strong Buy and seven a Buy.
• The company reported earnings of ($0.40) per share, exceeding expectations, but still fell short on revenue with $13.82 million against an anticipated $31.51 million.
• Insiders have recently sold a significant amount of stock, totaling over $2 million in transactions, leading to a decreased ownership stake among them.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $21.80 and last traded at $21.87, with a volume of 282065 shares traded. The stock had previously closed at $20.68.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Wedbush upped their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Jefferies Financial Group began coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. BTIG Research set a $28.00 price target on Stoke Therapeutics and gave the company a "buy" rating in a report on Monday, August 18th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Two analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $25.57.

Stoke Therapeutics Trading Down 1.8%

The business's 50-day simple moving average is $16.05 and its two-hundred day simple moving average is $11.52. The company has a market capitalization of $1.29 billion, a PE ratio of 27.60 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. On average, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 5,501 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total transaction of $109,304.87. Following the transaction, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. This trade represents a 22.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 14,922 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total transaction of $300,529.08. Following the transaction, the general counsel directly owned 18,176 shares in the company, valued at $366,064.64. The trade was a 45.08% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,719 shares of company stock valued at $2,063,359 in the last ninety days. Insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently modified their holdings of the stock. RTW Investments LP lifted its position in shares of Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after purchasing an additional 471,240 shares during the last quarter. Toronto Dominion Bank bought a new position in Stoke Therapeutics in the fourth quarter worth about $35,001,000. Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company's stock worth $18,515,000 after acquiring an additional 53,004 shares during the last quarter. Marshall Wace LLP lifted its holdings in Stoke Therapeutics by 7.9% in the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock worth $26,111,000 after acquiring an additional 168,771 shares during the last quarter. Finally, Siren L.L.C. lifted its holdings in Stoke Therapeutics by 12.4% in the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after acquiring an additional 247,347 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.